Características y resultados de los pacientes ingresados por COVID-19 durante la pandemia / Characteristics and results of patients admitted with COVID-19 during the pandemic

Objetivos: Describir la situación de los pacientes y de sus ingresos hospitalarios a causa de infección por SARS-CoV-2.Métodos: Estudio observacional retrospectivo de más de un mes de duración (marzo-abril) en el que se incluyeron pacientes ingresados en un hospital secundario con diagnóstico de infección por SARS-CoV-2. Los criterios de inclusión fueron: más de 18 años de edad en el momento de ingreso y diagnóstico de infección por SARS-CoV-2. Se recogieron datos demográficos y comorbilidades, datos clínicos al ingreso, fármacos recibidos durante el ingreso, datos analíticos y procedencia.Resultados: Se incluyeron 224 pacientes. La mediana de edad fue de 74 años (rango: 63-81) y 60,7% eran hombres. El 53,1% presentaba más de una comorbilidad. Las manifestaciones clínicas más frecuentes al ingreso fueron disnea (62,9%) y tos (62,5%), y el 25% tenía fiebre. De los tratamientos utilizados, destacan la hidroxicloroquina y azitromicina que han sido utilizados en el 91,5% y 73,2% de los pacientes, respectivamente. El 41,7% de los pacientes tenían linfopenia, y el 41,1% presentaba un dímero D >1.000 ng/ml. Conclusiones: Nuestro estudio muestra que las características predominantes en los pacientes hospitalizados por infección por SARS-CoV-2 en nuestro departamento durante la etapa temprana de la pandemia, han sido: hombres, pacientes mayores de 65 años, con más de una comorbilidad. Linfopenia y elevaciones del dímero D resultaron las alteraciones analíticas más típicas. Hidroxicloroquina y azitromicina fueron los dos fármacos que más han utilizado. (AU)

Objectives: Describe the situation of patients and their hospital admissions due to SARS-CoV-2 infection.Methods: Retrospective observational study lasting more than one month (March-April) including patients admitted to a secondary hospital with a diagnosis of SARS-CoV-2 infection. The inclusion criteria were: over 18 years of age at the time of admission and diagnosis of infection by SARS-CoV-2. Demographic data and comorbidities, clinical data on admission, drugs received during admission, analytical data and origin are collected.Results: 224 patients were included. The median age was 74 years (range: 63-81) and 60.7% were men. 53.1% had more than one comorbidity. The most frequent clinical manifestations on admission were dyspnea (62.9%) and cough (62.5%), and 25% had fever. Of the treatments used, hydroxy- chloroquine and azithromycin stand out, which have been used in 91.5% and 73.2% of patients, respectively. 41.7% of the patients had lymphopenia, and 41.1% had a D-dimer >1,000 ng/ml.Conclusions: Our study shows that the predominant characteristics in patients hospitalized for SARS-CoV-2 infection in our department during the early stage of the pandemic have been: men, patients over 65 years of age, with more than one comorbidity. Lymphopenia and D-dimer elevations were the most typical laboratory abnormalities. Hydroxychloroquine and azithromycin were the two drugs that have been used the most. (AU)

Perfil de toxicidad y adherencia del esquema farmacoterapéutico gemcitabina-carboplatino en cáncer de pulmón no microcítico / Toxicity Profile and Adherence to the Pharmacotherapeutic Regimen of Gemcitabine–carboplatin in Non-small Cell Lung Cancer

Objetivo Analizar la relación entre las dosis administradas de gemcitabina-carboplatino (GEM-CARBO) y la incidencia y grado de toxicidad, hematológica y renal, y la adherencia al tratamiento en pacientes con cáncer de pulmón no microcítico. Métodos Estudio retrospectivo de 37 meses de duración. El conjunto mínimo de datos para realizar el seguimiento de los pacientes se obtuvo con ayuda del programa informático Farmis-Oncofarm® y de las historias clínicas y farmacoterapéuticas. La toxicidad hematológica se evaluó de acuerdo con la Common Toxicity Criteria 3.0. La toxicidad renal se valoró a partir de los datos de concentración sérica de creatinina y el aclaramiento de creatinina. Resultados Se han incluido en el estudio 31 pacientes a los que se les administraron un total de 122 ciclos. La incidencia de anemia y neutropenia grado III fue de un 34,0 y un 30,8%, respectivamente, de trombocitopenia de grado III del 3,8% y de grado IV del 7,7%. No se ha identificado ningún caso de toxicidad renal. El 65,0% de los pacientes recibieron más del 85,0% de la dosis de carboplatino teórica planeada y el 58,0% de los pacientes recibieron más del 85,0% de la dosis de gemcitabina teórica planeada. Se retrasó la administración en el 18,0% de los ciclos prescritos. Conclusiones La indicación y prescripción del esquema GEM-CARBO se ha ajustado con unas evidencias científicas sólidas, pero su toxicidad hematológica ha limitado su uso y ha dificultado la administración de la intensidad de dosis prevista comprometiendo la efectividad del tratamiento (AU)

Objective To analyse the relationship between doses of gemcitabine–carboplatin (GEM-CARBO) administered and incidence and level of haematological and renal toxicity, and the adherence to the treatment in patients with non-small cell lung cancer. Methods Retrospective study, which lasted for 37 months. We were able to obtain the minimum set of data needed to carry out the follow-up with the help of Farmis-Oncofarm® software and the medical and pharmacotherapeutic records. The haematological toxicity was assessed in accordance with the Common Toxicity Criteria 3.0. Renal toxicity was evaluated using serum creatinine levels and creatinine clearance. Results Thirty-one patients were included in the study who were administered a total of 122 cycles. There was a 34.0% and 30.8% incidence of anaemia and grade 3 neutropenia, respectively. There was also a 3.8% and 7.7% incidence of grade 3 and grade 4 thrombocytopenia, respectively. No cases of renal toxicity were found. 65.0% of patients received more than 85.0% of the planned theoretical dosage of carboplatin and 58% of patients received more than 85.0% of the planned theoretical dosage of gemcitabine. Administration was delayed in 18.0% of the cycles prescribed. Conclusions The indication and prescription of the GEM-CARBO regimen was adjusted in accordance with solid scientific evidence, but its haematological toxicity limited its use and made it difficult to maintain the dose intensity foreseen in the study. This compromised the effectiveness of the treatment (AU)

Toxicity profile and adherence to the pharmacotherapeutic regimen of gemcitabine-carboplatin in non-small cell lung cancer.

OBJECTIVE: To analyse the relationship between doses of gemcitabine-carboplatin (GEM-CARBO) administered and incidence and level of haematological and renal toxicity, and the adherence to the treatment in patients with non-small cell lung cancer. METHODS: Retrospective study which lasted for 37 months. We were able to obtain the minimum set of data needed to carry out the follow-up with the help of Farmis-Oncofarm(®) software and the medical and pharmacotherapeutic records. The haematological toxicity was assessed in accordance with the Common Toxicity Criteria 3.0. Renal toxicity was evaluated using serum creatinine levels and creatinine clearance. RESULTS: Thirty-one patients were included in the study who were administered a total of 122 cycles. There was a 34.0% and 30.8% incidence of anaemia and grade 3 neutropaenia, respectively. There was also a 3.8% and 7.7% incidence of grade 3 and grade 4 thrombocytopaenia, respectively. No cases of renal toxicity were found. 65.0% of patients received more than 85.0% of the planned theoretical dosage of carboplatin and 58% of patients received more than 85.0% of the planned theoretical dosage of gemcitabine. Administration was delayed in 18.0% of the cycles prescribed. CONCLUSIONS: The indication and prescription of the GEM-CARBO regimen was adjusted in accordance with solid scientific evidence, but its haematological toxicity limited its use and made it difficult to maintain the dose intensity foreseen in the study. This compromised the effectiveness of the treatment.